TrialLancet (London, England)2017

Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study.

Olivier Lortholary et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.